Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181704 | 0.84 | ERN1 (0.38) | ERN1MCL1HCRTR1HCRTR2 | |
| SCHEMBL150019 | 0.82 | ERN1 (0.46) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL248719 | 0.82 | ERN1 (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL24947221 | 0.80 | ERN1 (0.44) | ERN1 | |
| Hydrochloric Acid SCHEMBL28586585 | 0.79 | ERN1 (0.44) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL18133931 | 0.77 | TDP1 (0.43) | ERN1MCL1TDP1 | |
| SCHEMBL28880933 | 0.77 | PRKDC (0.44) | ERN1MCL1LMNA | |
| SCHEMBL13814618 | 0.77 | ERN1 (0.36) | ERN1MCL1TDP1 | |
| SCHEMBL29911304 | 0.77 | ERN1 (0.36) | ERN1MCL1TDP1 | |
| SCHEMBL12961324 | 0.77 | MCL1 (0.34) | ERN1MCL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023177854-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230257362-A1 | TRIAZOLONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8232401-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2272516-A2 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | Japan Tobacco, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100261719-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100204271-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. | 2010-08-12 | — | — | US | disclosed |
| EP-2193132-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2010-06-09 | — | — | EP | disclosed |
| EP-2161258-A2 | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor | Japan Tabacco Inc. (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-7531554-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-2033954-A1 | 6-(HETEROCYCLE-SUBSTITUTED BENZYL)-4-OXOQUINOLINE COMPOUND AND USE OF THE SAME AS HIV INTEGRASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009004382-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204271-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | GRIN2D, KCNQ2, RCC1 | ERN1 3950/4885MCL1 2190/4885MEN1 1461/4885 |
| US-20230257362-A1 | TRIAZOLONE COMPOUND | WNK3, SLC10A1, WNK2 | ERN1 3980/4885MCL1 2075/4885MEN1 1725/4885 |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | ERN1 82/4885MCL1 3719/4885MEN1 4747/4885 |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | ERN1 82/4885MCL1 3719/4885MEN1 4747/4885 |
| US-20100261719-A1 | CHEMICAL COMPOUNDS | NCOA3, NR4A3, NR0B2 | ERN1 1745/4885MCL1 2195/4885MEN1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.